ADVERTISEMENT
Dead shark on concrete
Researchers Make Alternatives to Shark-Sourced Vaccine Ingredient
Synthetic variations of squalene, which is used to boost immune responses, could make vaccines more effective while reducing fisheries for struggling sharks.
Researchers Make Alternatives to Shark-Sourced Vaccine Ingredient
Researchers Make Alternatives to Shark-Sourced Vaccine Ingredient

Synthetic variations of squalene, which is used to boost immune responses, could make vaccines more effective while reducing fisheries for struggling sharks.

Synthetic variations of squalene, which is used to boost immune responses, could make vaccines more effective while reducing fisheries for struggling sharks.

vaccine

RSV vaccine design concept art
RSV Vaccines That Work?
Rachael Moeller Gorman | Feb 16, 2023 | 10+ min read
Multiple candidates are in Phase 3 clinical trials for older adults and pregnant women, with some getting close to approval in the United States.
Fluorescence image in purple and green of lymph node
Targeting Antigen “Sanctuary” in Lymph Nodes Could Make Vaccines Better
Natalia Mesa, PhD | Feb 10, 2023 | 3 min read
Researchers find that small sacks inside lymph nodes contain low proteolytic activity and act as safe havens for antigens.
<em >The Scientist</em>&rsquo;s Journal Club: Immunology
The Scientist’s Journal Club: Immunology
The Scientist’s Creative Services Team | 1 min read
Scientists present the latest research on the immune response against SARS-CoV-2, the influence of COVID-19 on future vaccine responses, and drivers of T cell development.
a newly hatched mosquito sits on top of water, with its discarded cocoon floating below
In Vitro Malaria Sporozoite Production May Lead to Cheaper Vaccines
Katherine Irving | Jan 20, 2023 | 4 min read
A method for culturing the infectious stage of the Plasmodium lifecycle could increase malaria vaccine production efficiency by tenfold, study authors say.
Sam Katz looks at the camera
Measles Vaccine Developer Samuel Katz Dies at 95
Lisa Winter | Nov 23, 2022 | 3 min read
He also worked on immunizations against polio, rubella, influenza, and more.
Discover new treatments for pandemic diseases
Treatments for Disease Pandemics
The Scientist’s Creative Services Team | 1 min read
Researchers develop new vaccines and therapeutics to combat the spread of infectious diseases.
person in white jacket putting bandaid on arm of child
Can We Predict How Well Someone Will Respond to a Vaccine?
Natalia Mesa, PhD | Nov 14, 2022 | 7 min read
Researchers find signatures pre- and post-vaccination that correlate with a more robust immune response. 
Illustration showing immunology during pregnancy
Infographic: How Immunology Can Influence Pregnancy Outcomes
Tobias R. Kollmann, Arnaud Marchant, and Sing Sing Way | Nov 14, 2022 | 3 min read
Pregnancy-induced changes in the immune system are key to a successful birth. Understanding those changes could allow researchers to protect both mother and child.
Scientific Breakthroughs with Cryogenic Electron Microscopy
The Scientist’s Creative Services Team and Thermo Fisher Scientific | 1 min read
Structures made via cryo-EM give researchers insights into SARS-CoV-2, HIV, neurological disorders, cancer, and more.
Illustration of pregnancy and the immune system
Modulating Immunity to Improve Pregnancy Outcomes
Tobias R. Kollmann, Arnaud Marchant, and Sing Sing Way | Nov 14, 2022 | 10+ min read
Aberrant immune activation, the main cause of prematurity and stillbirths, could be preventable through interventions such as maternal vaccination. 
a person fumigates a red brick pathway to control mosquitoes in the fight against Dengue virus.
European Medicines Agency Recommends Approving Takeda’s Dengue Vaccine
Katherine Irving | Oct 14, 2022 | 2 min read
In clinical trials, the new inoculation demonstrated greater protection for children and people older than 45 than the existing dengue vaccine.
Transforming Virology Research with Cryo-EM
The Scientist’s Creative Services Team and Thermo Fisher Scientific | 1 min read
Explore what researchers can do with Cryo-EM
A person in a white shirt activates a nasal spray
Oxford-AstraZeneca Nasal COVID-19 Vaccine Falters in Clinical Trial
Dan Robitzski | Oct 11, 2022 | 2 min read
Researchers say they’re abandoning the project in its current form—one of several that aims to induce what’s known as mucosal immunity against SARS-CoV-2.
News feature
Vector image of black body with head surrounded by white clouds
Multiple Possible Causes of Long COVID Come into Focus
Natalia Mesa, PhD | Sep 28, 2022 | 10+ min read
Recent studies have lent support for a variety of hypotheses explaining the debilitating symptoms affecting millions of people after SARS-CoV-2 infection.  
Fast-Tracking COVID-19 Research
The Scientist Creative Services Team in collaboration with Sartorius Corporation | 1 min read
Identifying molecular targets for SARS-CoV-2 therapeutics.
A germinal center inside a lymph node
Slow Vaccine Delivery May Maximize Immune Response
Alejandra Manjarrez, PhD | Sep 23, 2022 | 5 min read
A vaccine strategy involving formulation changes, an initial escalating dose, and a longer wait for booster immunization results in more-effective antibody production against HIV in rhesus monkeys, a study finds.
Histology of mouse lungs using purple and green staining on a white background. Left: a healthy lung. Right: a fibrotic lung.<br><br>
Immunotherapy Treats Fibrosis in Mice
Alejandra Manjarrez, PhD | Sep 15, 2022 | 4 min read
Researchers report that vaccination against proteins found on profibrotic cells reduced liver and lung fibrosis in laboratory rodents.
T Cells: A New Hope for Lasting Protection against SARS-CoV-2
The Scientist’s Creative Services Team | 1 min read
Alessandro Sette and Shane Crotty discuss the T cell response to SARS-CoV-2 and the implications for vaccine design and robust immune memory.
A translucent illustration of the BA.2.75 subvariant of SARS-CoV-2 against a black background
Experts Mixed on Risk of “Centaurus” Omicron Subvariant
Dan Robitzski | Aug 15, 2022 | 3 min read
BA.2.75 is spreading rampantly in India and has so far reached at least 20 other countries, but it doesn’t seem to be outcompeting other Omicron SARS-CoV-2 subvariants.
ADVERTISEMENT